Low & middle income vs Norway: Immunization, Hib3
Low & middle income
75.7%
in 2024
Norway
97.0%
in 2024
Low & middle income rank
29th
Norway rank
29th
Immunization, Hib3 over time
- Low & middle income
- Norway
How they compare
Norway currently reports 97.0% against 75.7% in Low & middle income, a difference of 21.3%.
That makes Norway's figure about 1.3 times Low & middle income's.
Across all 29 years both countries report, Norway has been ahead every year.
Low & middle income ranks 29th and Norway ranks 29th of 43 groups.
Norway has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Low & middle income | Norway | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.6% | 95.5% | 94.9% | Norway |
| 2000s | 15.3% | 94.1% | 78.8% | Norway |
| 2010s | 55.3% | 95.3% | 40.0% | Norway |
| 2020s | 72.8% | 96.8% | 24.0% | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Low & middle income or Norway?
- Norway, at 97.0% against 75.7% in Low & middle income as of 2024.
- What is the difference in immunization, hib3 between Low & middle income and Norway?
- 21.3%, with Norway ahead.
- How many years of comparable data are there for Low & middle income and Norway?
- 29 years are reported by both, from 1996 to 2024.
- How do Low & middle income and Norway rank globally for immunization, hib3?
- Low & middle income ranks 29th and Norway ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.